Table 2.
Percentage of studies reporting outcomes by therapeutic class, study design and data source
| Therapeutic class (%) | Study design** (%) | Data source*** (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| Outcome reported | AHTs (n = 53) | OADs (n = 35) | LLTs (n = 32) | Total* (n = 139) | Prospective (n = 65) | Retrospective (n = 54) | MEMS (n = 21) | Pharmacy claims (n = 73) |
| Clinical parameter | 30.8 | 28.6 | 34.4 | 28.1 | 40.0 | 29.6 | 52.4 | 17.8 |
| Event | 7.7 | 5.7 | 9.4 | 7.9 | 12.3 | 5.6 | 14.3 | 4.1 |
| None | 61.5 | 65.7 | 56.3 | 64.0 | 47.7 | 64.8 | 33.3 | 78.1 |
Results are presented as percentages of the number of studies in each group.
*
Includes studies with multiple treatment arms.
**
p = 0.0001 for test of independence of factors.
***
p = 0.004 for test of independence of factors. AHTs, antihypertensives; LLTs, lipid-lowering therapies; MEMS, medication event monitoring system; OADs, oral antidiabetics.